LUCEMYRA® should be taken orally, four times per day, for 5-7 days1

  • The usual LUCEMYRA starting dosage is three 0.18 mg tablets (0.54 mg) taken orally 4 times daily during peak withdrawal symptoms (generally, this is the first 5 to 7 days after the last use of an opioid)
  • There should be 5 to 6 hours between each dose
  • The total daily dosage of LUCEMYRA should not exceed 2.88 mg (16 tablets) and no single dose should exceed 0.72 mg (4 tablets)
  • LUCEMYRA can be taken with or without food
  • LUCEMYRA treatment may be continued for up to 14 days with dosing guided by symptoms
  • Dose adjustment of LUCEMYRA is required in patients with hepatic or renal impairment

In the prescription, include instructions for discontinuing LUCEMYRA1

  • Discontinue LUCEMYRA with a gradual dose reduction over a 2- to 4-day period (e.g., reducing by 1 tablet per dose every 1 to 2 days)

LUCEMYRA has been studied concomitantly with commonly used therapies for Opioid Use Disorder, such as buprenorphine, methadone, and naltrexone1

  • In a double-blind placebo-controlled study of 30 subjects maintained on buprenorphine (16-24 mg/day) concomitantly administered LUCEMYRA up to 2.88 mg/day, no pharmacokinetic or pharmacodynamic interactions between LUCEMYRA and buprenorphine were seen
  • LUCEMYRA and methadone both prolong the QT interval. ECG monitoring is recommended in patients receiving methadone and LUCEMYRA
  • It is possible that oral naltrexone efficacy may be reduced if used concomitantly within 2 hours of LUCEMYRA
    • This interaction is not expected if naltrexone is administered by non-oral routes


  1. LUCEMYRA® (lofexidine) [Prescribing Information]. USWM, LLC; 2018.